Malignancy in STAT3 Deficient Hyper IgE Syndrome

J Clin Immunol. 2022 Apr;42(3):699-702. doi: 10.1007/s10875-021-01197-y. Epub 2022 Jan 21.

Authors

Amanda Urban¹; NCI Lymphoma Physicians Consortium; Stefania Pittaluga²; Case Western Physicians Consortium; Alexandra F Freeman³

Collaborators

Christopher Melani, Mark Roschewski, Wyndham Wilson, Haig Tcheurekdjian, Neha Desai, Irini Pateva

Affiliations

¹ Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
² Laboratory of Pathology, Clinical Center, National Cancer Institute, NIH, Bethesda, MD, USA.
³ Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, NIAID, 10 Center Drive, Room 12C103, Bethesda, NIHMD, USA. freemaal@mail.nih.gov.

PMID: 35059947
DOI: 10.1007/s10875-021-01197-y

No abstract available

Publication types

Letter
Research Support, N.I.H., Intramural

MeSH terms

Humans
Job Syndrome* / diagnosis
Job Syndrome* / genetics
Mutation
Neoplasms*
STAT3 Transcription Factor / genetics
STAT3 Transcription Factor / metabolism

Substances

STAT3 Transcription Factor
STAT3 protein, human